Introduction
============

The sustainable development goals (SDG) identify access to quality medicines as a key component of universal health coverage (UHC).[@R1] The SDGs also reflect a global recognition of the need to tackle the growing burden of noncommunicable diseases, including cancer. The World Health Organization's*WHO Model list of essential medicines* includes a section on anti-neoplastic medicines that countries can use to inform the development of their own national essential medicines lists. Beyond inclusion in national essential medicines lists,[@R2]^--^[@R6] little is known about the use of cancer medicines at a country level. This is an important gap, particularly as countries are striving to improve access to care and financial protection through UHC.

The Lancet Commission on Essential Medicines for Universal Health Coverage[@R7]^,^[@R8] called for the continuous and global monitoring of access to essential medicines (including anti-cancer medicines) in the form of routine data disaggregated by gender, ethnicity, education, residential location and wealth quintile. As these data are not readily available in many settings, it is important to leverage different sources of evidence to inform progress.[@R9]^,^[@R10] Multicountry studies on access to anti-cancer medicines in low- and middle-income countries have used the inclusion of medicines in national essential medicines or reimbursement lists and formularies[@R2]^--^[@R6]^,^[@R11] and their availability on the market and applicable copayments[@R11] as proximate indicators of access. Country-level studies have used national essential medicines lists and formularies,[@R12]^,^[@R13] sales data,[@R14]^--^[@R16] surveys[@R17] and patient-level data from medical records[@R18]^--^[@R23] to assess access to anti-cancer medicines in low- and middle-income countries. However, to our knowledge, few of the existing studies[@R15] or official statistics[@R24] have assessed the changes in use of anti-cancer medicines during the past decade of coverage expansion in low- and middle-income countries.

As the number of new cancer cases worldwide is expected to increase from 18.1 million in 2018 to 29.5 million in 2040[@R25] and the need to improve access to medicines is high on the global agenda,[@R8] we need evidence on the use of anti-neoplastic medicines at a country level. In this study, we use routinely collected market sales data to assess how sales of the anti-cancer medicines included in the 2017 *WHO Model list of essential medicines*[@R26] have evolved over time in six countries.

Methods
=======

Country selection
-----------------

We selected countries to include in our study based on the following criteria. First, we identified countries working towards UHC, and that have set up national public or private third-party payment systems or implemented other relevant pharmaceutical coverage policies within the government health system, in the last decade. Second, we chose countries in which IQVIA sales data on the medicines of interest were available and cover both public and private sectors, and hospital, as well as retail sectors. Third, we focused on countries from the same income group (i.e. middle income) and continent to make comparisons more meaningful. China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand met these criteria. We provide a summary of the demographic and socioeconomic characteristics of these six countries in [Table 1](#T1){ref-type="table"}.

###### Demographic and socioeconomic characteristics of the six countries included in a study of anti-cancer medicine sales during 2007--2017

  Characteristic                                                                              China      Indonesia   Kazakhstan   Malaysia   Philippines   Thailand
  ------------------------------------------------------------------------------------------- ---------- ----------- ------------ ---------- ------------- ----------
  Population in 2017 (million)^a^                                                             1386.4     264.6       18.0         31.1       105.2         69.2
  Percentage of the population aged 0--14 years in 2017^b^                                    17.9       26.9        27.9         24.3       31.5          17.4
  Percentage of the population aged ≥ 65 years in 2017^c^                                     10.3       5.7         7.1          6.4        4.9           11.4
  GDP per capita, PPP in 2017 (current international dollars)^d^                              16 782.2   12 279.2    26 490.8     30 025.2   8340.3        17 917.2
  Current health expenditure per capita, PPP in 2017 (current international dollars)^e^       841.1      367.9       820.4        1110.4     371.7         670.9
  Domestic general government health expenditure in 2017 (% of total health expenditure)^e^   56.7       49.1        62.2         52.0       35.0          79.0
  All-cancer incidence per 100 000 population in 2017^f^                                      325        120         215          155        122           224

GDP: gross domestic product; PPP: purchasing power parity.

^a^ The World Bank.[@R27]

^b^ The World Bank.[@R28]

^c^ The World Bank.[@R29]

^d^ The World Bank.[@R30]

^e^ WHO Global Health Expenditure Database.[@R31]

^f^ Global Burden of Disease Collaborative Network.[@R32] Compare data with the global all-cancer incidence per 100 000 population of 319 in 2017.[@R32]

Medicine selection
------------------

We considered all 49 anti-neoplastic medicines (defined on the basis of their active ingredients) listed in sections 8.2 "Cytotoxic and adjuvant medicines" and 8.3 "Hormones and antihormones" of the 2017 WHO model list.[@R26] We excluded five supportive medications used to prevent or relieve the side-effects of anti-neoplastic treatment. We also excluded five medications that are listed in other therapeutic classes, as well as in sections 8.2 or 8.3. For example, methotrexate is also listed in section 30.2 of the model list for the treatment of rheumatoid arthritis; based on the formulation of methotrexate, it is not possible to distinguish between indications (further details available in the data repository).[@R33] The number of medicines that we selected for this study was therefore 39 ([Box 1](#B1){ref-type="boxed-text"}).

###### Anti-neoplastic drugs and their defined daily dose^a^ included in the study of anti-cancer medicine sales in six countries, 2007--2017

### Traditional chemotherapy

Asparaginase 14 000 units; Bendamustine 17 mg; Bleomycin 3 mg; Capecitabine 3000 mg; Carboplatin 25 mg; Chlorambucil 2 mg;^b^ Cisplatin 6.75 mg; Cyclophosphamide 250 mg; Cytarabine 50 mg;^b^ Dacarbazine 100 mg; Dactinomycin 0.32 mg; Daunorubicin 20 mg;^b^ Docetaxel 6.43 mg; Doxorubicin 5 mg; Etoposide 50 mg; Fludarabine 10 mg;^b^ Fluorouracil 150 mg; Gemcitabine 200 mg; Hydroxycarbamide 1750 mg; Ifosfamide 700 mg; Irinotecan 30 mg; Mercaptopurine 175 mg; Oxaliplatin 11 mg; Paclitaxel 15 mg; Procarbazine 50 mg;^b^ Tioguanine 25 mg;^b^ Tretinoin (or all-trans retinoid acid) 10 mg;^b^ Vinblastine 11.61 mg; Vincristine 360 mg; and Vinorelbine 18 mg

### Targeted therapies

Dasatinib 120 mg; Imatinib 500 mg; Nilotinib 600 mg; Rituximab 32 mg; and Trastuzumab 20 mg

### Endocrine therapy

Anastrozole 1 mg; Bicalutamide 50 mg; Leuprorelin 1 mg; and Tamoxifen 20 mg

^a^ Defined daily dose according to German Institute for Medical Documentation,[@R34] unless otherwise indicated.

^b^ Defined daily dose were not available from the German Institute for Medical Documentation, we therefore adopted the strength of the smallest common unit (e.g. smallest tablet) as defined daily dose.

Data source
-----------

IQVIA conducts multisample audits of pharmaceutical purchase data based on invoices from pharmacies, wholesalers, distributors and manufacturers in the hospital and retail sectors in several countries worldwide (further details available in data repository).[@R33]^,^[@R35]^,^[@R36] The proprietary data are extrapolated to represent national-level sales. Quality checks (e.g. comparison with manufacturer data) are conducted to ensure the accuracy and representativeness of the data.[@R36] We extracted quarterly data on sales volumes of all anti-neoplastic medicines of interest from 2007 to 2017 from the IQVIA database; complete data for Kazakhstan and Malaysia were only available from 2008 onwards, so we used 2008 as the baseline for both these countries. The data set included country, setting (retail or hospital), generic name, quarter, year, strength, formulation, units per pack and number of packs sold.

The assumed average maintenance dose per day for a medicine used for its main indication in adults, defined by the Anatomical Therapeutic Chemical Classification System according to its administration route, is referred to as the defined daily dose.[@R37] The defined dose provides a common unit of analysis that can be used to study the use of medicines over time and across therapeutic classes and population groups. The WHO Collaborating Centre for Drug Statistics Methodology assigns a defined daily dose index for many drugs, but made the decision not to assign defined daily doses for medicines with highly individualized treatment schedules, such as anti-neoplastic medicines.[@R37] We therefore used defined daily dose information provided by the German Institute for Medical Documentation and Information, which defines daily dose based on the standard dose in the manufacturer submission for marketing authorization.[@R34] If we were not able to obtain a defined daily dose for a particular medicine from the German Institute for Medical Documentation and Information, we adopted the smallest common unit used in the six countries as a reference ([Box 1](#B1){ref-type="boxed-text"}).

We used country-specific estimates of new cancer cases available by year for the entire study period from the 2017 Global Burden of Disease (GBD) study.[@R32]

Analysis
--------

Using information on the strength of each medicine, number of units per pack and number of packs sold, we estimated the total milligrams (or active units for asparaginase) sold. We divided the total quantity sold by the reference defined daily dose for that particular medicine to estimate the total number of defined daily doses sold. We defined sales volume as the estimated number of defined daily doses sold per country and per year for each of the three types of anti-cancer treatment (traditional chemotherapy, targeted therapy and endocrine therapy). We also calculated the number of defined daily doses sold per new cancer case.

Ethics
------

Ethical approval was granted by the Institutional Review Board of Harvard Pilgrim Health Care.

Results
=======

Cancer incidence
----------------

Of the countries studied, China is the most populous and also, according to GBD data,[@R32] the country with the highest all-cancer incidence (325 per 100 000 in 2017; [Table 1](#T1){ref-type="table"}). The highest number of new cancer cases for both 2007 and 2017 was observed in China, as well as the largest absolute (1 807 036.83 cases) and relative (1.65-fold) increase ([Table 2](#T2){ref-type="table"}). GBD data[@R32] indicate that Indonesia, the second-most populous of the countries studied, had the second-highest number of cancer cases in both 2007 and 2017 and the second-largest increase in absolute numbers (68 505.81 cases), but not in relative numbers (1.28-fold). We noted that the second-highest relative increase in the number of new cancer cases (1.53-fold; from 2008 to 2017 in this case) occurred in Malaysia.

###### All-cancer incidence and sales volumes of anti-cancer medicines in six countries in 2007 (or 2008) and 2017

  Data                                               China            Indonesia       Kazakhstan^a^   Malaysia^a^    Philippines    Thailand
  -------------------------------------------------- ---------------- --------------- --------------- -------------- -------------- ---------------
  **New cancer cases, all cancers^b^**                                                                                              
  Year 2007 or 2008^a^                               2 781 760.17     242 435.72      35 281.97       31 045.63      87 922.57      120 420.79
  Year 2017                                          4 588 797.00     310 941.53      38 503.55       47 594.47      126 203.23     157 914.48
  Absolute increase                                  1 807 036.83     68 505.81       3221.57         16 548.84      38 280.66      37 493.69
  Relative increase, *x*-fold)                       1.65             1.28            1.09            1.53           1.44           1.31
  **Chemotherapy**                                                                                                                  
  Total no. defined daily doses sold^c^                                                                                             
    Year 2007 or 2008^a^                             80 222 871.95    965 421.50      1 075 377.68    2 023 814.87   1 594 213.68   6 182 965.79
    Year 2017                                        202 691 916.50   11 737 244.72   1 307 816.88    2 715 687.49   3 867 712.03   12 354 259.40
    Absolute increase                                122 469 044.55   10 771 823.22   232 439.20      691 872.62     2 273 498.34   6 171 293.91
    Relative increase, *x*-fold                      2.53             12.16           1.22            1.34           2.43           2.00
  No. defined daily doses sold per new cancer case                                                                                  
    Year 2007 or 2008^a^                             28.84            3.98            30.48           65.19          18.13          51.34
    Year 2017                                        44.17            37.75           33.97           57.06          30.65          78.23
    Absolute increase                                15.33            33.77           3.49            −8.13          12.51          26.89
    Relative increase, *x*-fold                      1.53             9.48            1.11            0.88           1.69           1.52
  **Targeted therapy**                                                                                                              
  Total no. defined daily doses sold^c^                                                                                             
    Year 2007 or 2008^a^                             333 010.55       9 685.43        1 253.75        39 124.13      37 116.25      125 958.25
    Year 2017                                        11 281 751.09    488 889.37      365 575.96      400 541.29     217 806.95     1 104 714.19
    Absolute increase                                10 948 740.54    479 203.94      364 322.21      361 417.17     180 690.70     978 755.94
    Relative increase, *x*-fold                      33.88            50.48           291.59          10.24          5.87           8.77
  No. defined daily doses sold per new cancer case                                                                                  
    Year 2007 or 2008^a^                             0.12             0.04            0.04            1.26           0.42           1.05
    Year 2017                                        2.46             1.57            9.49            8.42           1.73           7.00
    Absolute increase                                2.34             1.53            9.46            7.16           1.31           5.95
    Relative increase, *x*-fold                      20.54            39.36           267.19          6.68           4.09           6.69
  **Endocrine therapy**                                                                                                             
  Total no. defined daily doses sold^c^                                                                                             
    Year 2007 or 2008^a^                             34 219 204.50    1 394 979.75    1 771 683.00    3 066 676.50   2 890 588.06   6 003 971.15
    Year 2017                                        129 391 344.55   3 979 765.31    2 323 521.75    5 338 724.85   5 955 772.99   11 275 412.09
    Absolute increase                                95 172 140.05    2 584 785.56    551 838.75      2 272 048.35   3 065 184.93   5 271 440.94
    Relative increase, *x*-fold                      3\. 78           2.85            1.31            1.74           2.06           1.88
  No. defined daily doses sold per new cancer case                                                                                  
    Year 2007 or 2008^a^                             12.30            5.75            50.21           98.78          32.88          49.86
    Year 2017                                        28.20            12.80           60.35           112.17         47.19          71.40
    Absolute increase                                15.90            7.05            10.13           13.39          14.32          21.54
    Relative increase, *x*-fold                      2.29             2.22            1.20            1.14           1.44           1.43

^a^ Complete sales data for Kazakhstan and Malaysia were only available from 2008, therefore we used the 2008 data as the baseline for these countries.

^b^ Global Burden of Disease Collaborative Network.[@R32]

^c^ Data available on request from IQVIA.

Sales volumes
-------------

The sales data indicated that, of the six countries studied, the highest number of defined daily doses of traditional chemotherapy was sold in China in both 2007 and 2017 ([Table 2](#T2){ref-type="table"}); China also demonstrated the highest absolute increase in defined daily doses of traditional chemotherapy sold from 2007 to 2017. However, the largest relative increase (12.16-fold) was observed in Indonesia.

Overall, the number of defined daily doses of traditional chemotherapy, targeted therapy and endocrine therapy sold per new cancer case increased over time for all six countries studied, with the exception of traditional chemotherapy in Malaysia ([Fig. 1](#F1){ref-type="fig"}, [Fig. 2](#F2){ref-type="fig"} and [Fig. 3](#F3){ref-type="fig"}).

![Defined daily doses of traditional chemotherapy sold per new cancer case in six countries from 2007 (or 2008) to 2017](BLT.19.243998-F1){#F1}
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In terms of defined daily doses per incident cancer case, for traditional chemotherapy the greatest relative increase from baseline occurred in Indonesia, where sales increased from 3.98 in 2007 to 37.75 in 2017. The highest number of defined daily doses per new case in 2017 was sold in Thailand (78.23). Although the total sales volume (in defined daily doses) increased in Malaysia from 2008 (2 023 814.87) to 2017 (2 715 687.49), this increase was by a lower proportion (1.34-fold) than the reported increase in the number of new cancer cases (1.53-fold); Malaysia therefore observed a decrease from 65.19 defined daily doses sold per new case in 2008 to 57.06 in 2017.

For targeted therapies, the highest number of defined daily doses per new cancer case in 2017 was sold in Kazakhstan, in which we observed the largest relative increase from 0.04 in 2008 to 9.49 in 2017. Of the five targeted therapies considered in this study ([Box 1](#B1){ref-type="boxed-text"}), trastuzumab and imatinib were sold in the largest quantities per new cancer case in all countries. For endocrine therapies, the largest numbers of defined daily doses of endocrine therapies per new cancer case (112.17) were sold in Malaysia in 2017, while both China and Indonesia more than doubled their numbers of defined daily doses sold per new cancer case from 2007 to 2017. Of the four endocrine medicines included in this study ([Box 1](#B1){ref-type="boxed-text"}), tamoxifen was the most widely sold endocrine therapy in all countries.

Discussion
==========

Our data show an overall increase in the sales of anti-cancer therapies in China, Indonesia, Kazakhstan, Malaysia (increase in overall chemotherapy sold, although a slight decrease per new cancer case), Philippines and Thailand during our study period. During this time, the six countries continued working towards the goals of achieving UHC. Given the high cost of cancer treatment, the expansions these countries have made in health-care coverage over the last decade will likely have played an important role in enabling greater use of these medicines. The largest increase occurred in defined daily doses of traditional chemotherapy sold in Indonesia between 2014 and 2015, which is when implementation of UHC began in that country. In addition to a higher availability of cancer medicines, improved access to a health-care system as a result of progress in UHC could have led to earlier diagnoses (at a stage amenable to treatment), contributing to an increased use of cancer medicines.

While the overall increase in sales of anti-cancer medicines from 2007 (or 2008) to 2017 in each country suggests increased access by the populations, aggregated results hide potential disparities in access between groups within a population. Two studies in Thailand found differences in the use of medicines between members of different insurance schemes. One study described differences in the type of treatment received and health outcomes between individuals with colorectal cancer insured under the UHC scheme for the general population and those in the civil servant scheme.[@R22] Disparities in survival were also found for lymphoma patients, and mainly attributed to limited access to rituximab for UHC-insured patients at the time of the study (2003--2006).[@R23] Two studies from China on patterns of prescribing for patients with breast cancer highlighted limited access to trastuzumab for patients overexpressing human epidermal growth factor receptor 2 (HER-2).[@R18]^,^[@R20] One of these two multicentre studies found that, between 2011 and 2014, only 31 (28.4%) of 109 patients overexpressing HER-2 were treated with trastuzumab.[@R20] A 2011 study in Malaysia found that only 19% of 172 patients younger than 70 years with HER-2-positive breast cancer stage I to III received trastuzumab within 1 year of diagnosis, which the authors attributed to its high cost and insufficient public funding for the treatment.[@R21] Despite these earlier findings highlighting limited access, official statistics show that the use of trastuzumab has increased over time (particularly in the public sector) following inclusion in the national formulary in 2008.[@R24]

As global spending on cancer treatment continues to rise, new therapies continue to enter the market and new indications are being approved for medicines already available,[@R38] countries will increasingly face challenges in enabling access to new therapies in an equitable way. Budgetary constraints play an important role in access to highly priced medicines, such as the five targeted therapies included in this study. In the absence of large discounts as part of differential pricing or industry access programmes, it will be challenging for middle-income countries working towards UHC to provide cancer medicines equitably to all patients in need. In Thailand for example, UHC-insured patients have access to medicines on the national essential medicines list and civil servants have access to all medicines on the Thai market.[@R14]^,^[@R15] To facilitate the coverage of highly priced medicines, Thailand has engaged in compulsory licensing, price negotiation and health technology assessment, and created a separate section on the essential medicines list (E2) used for centralized procurement, among other measures.[@R15] Similarly, in China, coverage of medicines differed between provinces and insurance schemes before 2018.[@R39] Generally, coverage with the Urban Employee Basic Medical Insurance scheme is more generous than the Urban Resident Basic Medical Insurance scheme and both provide greater coverage than the New Rural Cooperative Medical Scheme. To help municipalities (ultimately responsible for payment of medicines) cover medicines in the Basic Medical Insurance scheme, the Chinese Government has engaged in price negotiation with manufacturers to secure more competitive prices. Further, since 2019, provinces are required to cover all medicines included in the Basic Medical Insurance list (including the national essential medicines list); previously there was some flexibility for provinces to either exclude some medicines listed as essential (in the national list) from coverage, or to cover some medicines not listed as essential.[@R40]

Our study had several limitations. First, we used national-level sales data of anti-cancer medicines included in the 2017 *WHO Model list of essential medicines*; sales data do not tell us whether the medicine was eventually prescribed, dispensed and administered to the patient. If procurement quantities were inaccurate, or less patients presented than in previous years, sales may differ from actual use. Anti-cancer treatments included in the 2017 WHO model list are a subset of all available anti-cancer medicines; this subset is selected by the WHO Expert Committee on the Selection and Use of Essential Medicines by considering the burden of disease and responsiveness of the indicated cancer to pharmacotherapy. We had no access to patient-level data on the actual conditions treated, regimens, insurance status, co-payments, income, education or the many other factors that can influence the use of medicines. Our measure, defined daily dose, is a way to summarize and compare sales volumes across products and does not necessarily reflect the way in which these medicines are actually prescribed. Since we had no information on the indications for which these medicines were used in clinical practice (and most of these medicines can be used for different types of cancers), we could only attempt a crude adjustment for use by the total number of new cancer cases per country and year. Furthermore, the quality of the available data on cancer incidence may differ between countries, which may impact the reliability of inter-country comparisons.

Second, we cannot judge whether the sales levels we observed are sufficient to appropriately treat all cancer patients in a given country. The sales differences we identified between the six countries cannot be attributed to any specific cause, such as financial barriers, training and infrastructure, lack of insurance coverage, differences in clinical guidelines or stage at diagnosis, all of which might partially explain sales differences.

Finally, while IQVIA data are nationally representative and include the relevant channels (public and private sectors; hospital and retail settings) where cancer medicines are transacted, medicines procured through special channels (e.g. donations) may not be included in the IQVIA sample and therefore may not be captured in the data.

Despite the limitations described here, studies using routinely aggregated sales data over time can fill an important knowledge gap in the use of medicines. Such studies can be complemented by other research based on higher-resolution patient-level data (e.g. health insurance claims data, medical records and socioeconomic status),[@R9]^,^[@R41] allowing assessments of equity in access. Future studies also need to assess the affordability of cancer medicines at the household and system level. Monitoring sales in the context of insurance coverage expansions is important to identify progress and challenges in improving access to anti-cancer medicines, contributing to the SDG agenda. Our study has taken a first step in that direction.
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